Burden of Illness in Geographic Atrophy: A Study of Vision-Related Quality of Life and Health Care Resource Use

References

• Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37(5):819–835. doi:10.1097/IAE.0000000000001392
   PubMed Web of Science ®Google Scholar
• Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079–1091. doi:10.1016/j.ophtha.2013.11.023
   PubMed Web of Science ®Google Scholar
• Lindblad AS, Lloyd PC, Clemons TE, et al.; Age-Related Eye Disease Study Research Group. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009;127(9):1168–1174.
   PubMedGoogle Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Rees A, Zekite A, Bunce C, Patel PJ. How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration? Eye. 2014;28:832–837. doi:10.1038/eye.2014.103
   PubMed Web of Science ®Google Scholar
• Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012;119(3):571–580. doi:10.1016/j.ophtha.2011.09.027
   PubMed Web of Science ®Google Scholar
• Bindewald A, Schmitz-Valckenberg S, Jorzik JJ, et al. Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration. Br J Ophthalmol. 2005;89(7):874–878. doi:10.1136/bjo.2004.057794
   Web of Science ®Google Scholar
• Ly A, Nivison-Smith L, Assaad N, Kalloniatis M. Fundus autofluorescence in age-related macular degeneration. Optom Vis Sci. 2017;94(2):246–259. doi:10.1097/OPX.0000000000000997
   Web of Science ®Google Scholar
• Sunness JS, Gonzalez-Baron J, Applegate CA, et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology. 1999;106(9):1768–1779. doi:10.1016/S0161-6420(99)90340-8
   PubMed Web of Science ®Google Scholar
• Taylor DJ, Jones L, Binns AM, Crabb DP. ‘You’ve got dry macular degeneration, end of story’: a qualitative study into the experience of living with non-neovascular age-related macular degeneration [published online May 22, 2019]. Eye (Lond). doi:10.1038/s41433-019-0445-8
   Web of Science ®Google Scholar
• Sunness JS, Rubin GS, Applegate CA, et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology. 1997;104(10):1677–1691. doi:10.1016/S0161-6420(97)30079-7
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Bailey CC, Johnston RL, et al. Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125(6):842–849. doi:10.1016/j.ophtha.2017.11.036
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, et al. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006;17(3):257–266.
   PubMed Web of Science ®Google Scholar
• Orr S. Disease burden associated with geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016;57(12):21.
   Web of Science ®Google Scholar
• Chakravarthy U, Bailey C, Johnston RL, et al. Direct ophthalmic healthcare resource use among geographic atrophy patients in a large cohort from the United Kingdom. Presented at: American Academy of Ophthalmology Annual Meeting; October 16, 2016; Chicago, IL.
   Google Scholar
• Roh M, Selivanova A, Shin HJ, Miller JW, Jackson ML. Visual acuity and contrast sensitivity are two important factors affecting vision-related quality of life in advanced age-related macular degeneration. PLoS One. 2018;13(5):e0196481. doi:10.1371/journal.pone.0196481
   PubMed Web of Science ®Google Scholar
• Stevenson MR, Hart PM, Montgomery AM, McCulloch DW, Chakravarthy U. Reduced vision in older adults with age related macular degeneration interferes with ability to care for self and impairs role as carer. Br J Ophthalmol. 2004;88(9):1125–1130. doi:10.1136/bjo.2003.032383
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM): FY 2017 version. 2017. Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm. Accessed March 15, 2019.
   Google Scholar
• World Health Organization. ICD-11 for mortality and morbidity statistics. 2018. Available from: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/574366657. Accessed March 7, 2019.
   Google Scholar
• Sivaprasad S, Tschosik E, Kapre A, et al. Reliability and construct validity of the NEI VFQ-25 in a subset of patients with geographic atrophy from the phase 2 Mahalo study. Am J Ophthalmol. 2018;190:1–8. doi:10.1016/j.ajo.2018.03.006
   PubMed Web of Science ®Google Scholar
• World Medical Association. WMA Declaration of Helsinki – ethical principles for medical research involving human subjects. 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed March 21, 2019.
   Google Scholar
• International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). 2015. Available from: https://www.pharmacoepi.org/resources/policies/guidelines-08027/. Accessed March 21, 2019.
   Google Scholar
• Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Qquestionnaire. Arch Ophthalmol. 2001;119(7):1050–1058. doi:10.1001/archopht.119.7.1050
   PubMed Web of Science ®Google Scholar
• Jaeschke R, Singer J, Guyatt GH; Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–415. doi:10.1016/0197-2456(89)90005-6
   PubMedGoogle Scholar
• Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50(8):3629–3635. doi:10.1167/iovs.08-3225
   PubMed Web of Science ®Google Scholar
• Orr P, Rentz AM, Margolis MK, et al. Validation of the National Eye Institute Visual Function Qquestionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(6):3354–3359. doi:10.1167/iovs.10-5645
   PubMed Web of Science ®Google Scholar
• Yaspan BL, Williams DF, Holz FG, et al.; MAHALO Study Investigators. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med. 2017;9(395):f1443. doi:10.1126/scitranslmed.aaf1443
   Web of Science ®Google Scholar
• Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol. 2018;12:2483–2491. doi:10.2147/OPTH.S185052
   PubMed Web of Science ®Google Scholar
• Department of Health. Certification of vision impairment. Explanatory notes for consultant ophthalmologists and hospital eye clinic staff in England. 2017. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/637590/CVI_guidance.pdf. Accessed January 11, 2019.
   Google Scholar
• Green D, Ducorroy G, McElnea E, et al. The cost of blindness in the Republic of Ireland 2010–2020. J Ophthalmol. 2016;2016:4691276. doi:10.1155/2016/4691276
   Web of Science ®Google Scholar
• CNIB Foundation. What is blindness? 2018. Available from: https://www.cnib.ca/en/sight-loss-info/blindness/what-blindness?region=gta. Accessed January 11, 2019.
   Google Scholar
• Finger RP, Fimmers R, Holz FG, Scholl HP. Prevalence and causes of registered blindness in the largest federal state of Germany. Br J Ophthalmol. 2011;95(8):1061–1067. doi:10.1136/bjo.2010.194712
   PubMed Web of Science ®Google Scholar
• McCloud C, Khadka J, Gilhotra JS, Pesudovs K. Divergence in the lived experience of people with macular degeneration. Optom Vis Sci. 2014;91(8):966–974. doi:10.1097/OPX.0000000000000320
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Tschosik EA, Guymer RH, et al. Living with geographic atrophy: an ethnographic study. Ophthalmol Ther. 2019;8(1):115–124. doi:10.1007/s40123-019-0160-3
   PubMed Web of Science ®Google Scholar
• Rudnicka AR, Kapetanakis VV, Jarrar Z, et al. Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis. Am J Ophthalmol. 2015;160(1):85–93.e3. doi:10.1016/j.ajo.2015.04.003
   PubMed Web of Science ®Google Scholar
• Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125(3):369–390. doi:10.1016/j.ophtha.2017.08.038
   PubMed Web of Science ®Google Scholar
• Lotery A, Xu X, Zlatava G, Loftus J. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol. 2007;91(10):1303–1307. doi:10.1136/bjo.2007.116939
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Lieske HB, Tran I, Turpcu A, Colman S. Societal costs associated with neovascular age-related macular degeneration in the United States. Retina. 2016;36(2):285–298. doi:10.1097/IAE.0000000000000717
   PubMed Web of Science ®Google Scholar
• Jaffe DH, Chan W, Bezlyak V, Skelly A. The economic and humanistic burden of patients in receipt of current available therapies for nAMD. J Comp Eff Res. 2018;7(11):1125–1132. doi:10.2217/cer-2018-0058
   Web of Science ®Google Scholar
• Rathi S, Andrews C, Greenfield DS, Stein JD. A comparison of resource use and costs of caring for patients with exfoliation syndrome glaucoma versus primary open-angle glaucoma. Am J Ophthalmol. 2019;200:100–109. doi:10.1016/j.ajo.2018.12.024
   Web of Science ®Google Scholar
• Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005;89(10):1245–1249. doi:10.1136/bjo.2005.067355
   PubMed Web of Science ®Google Scholar
• Clegg JP, Guest JF, Lehman A, Smith AF. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol. 2006;13(4):263–274. doi:10.1080/09286580600801044
   PubMed Web of Science ®Google Scholar
• Garattini L, Castelnuovo E, Lanzetta P, Viscarra C, Ricci E, Parazzini F; CARMA Study Group. Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments. A multicenter, prospective 1-year study. Eur J Health Econ. 2004;5(1):22–27. doi:10.1007/s10198-003-0198-x
   Google Scholar
• Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (an AOS thesis). Trans Am Ophthalmol Soc. 2009;107:311–324.
   PubMedGoogle Scholar